首页> 外文期刊>Biosciences Biotechnology Research Asia >Evaluation of antimicrobial activity of Lactobacillus casei and Lactobacillus fermentum metabolites on the Shigella flexneri clinical samples.
【24h】

Evaluation of antimicrobial activity of Lactobacillus casei and Lactobacillus fermentum metabolites on the Shigella flexneri clinical samples.

机译:弗氏志贺氏菌临床样品上干酪乳杆菌和发酵乳杆菌代谢产物的抗菌活性评估。

获取原文
获取原文并翻译 | 示例
       

摘要

Bacillary dysentery caused by Shigella is one of the most important factors characterized by acute diarrhea in developed and developing countries. Probiotics reduce intensity risk of intestinal diseases. This study evaluates influences of Lactobacillus casei and Lactobacillus fermentum metabolites against Shigella Flexneri isolated from clinical samples. Antibiotic resistance of clinical samples of Shigella and Lactobacillus casei and Lactobacillus fermentum were assessed using agar-based minimal inhibitory concentration assay. 34 clinical samples of Shigella flexneri from patients were assayed for the antimicrobial activity of Lactobacillus metabolites using broth micro dilution method, minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC). Standard bacterial growth curves were drawn up by performance of turbidometric measurements to compare antibacterial effects of Lactobacilli metabolites against clinical samples. Antibiogram was carried out for 34 samples with positive culture. Antibiotic resistant bacteria were revealed for tetracycline, streptomycin and tobramycin. In this study chloramphenicol, tobramycin and amikacin resistance in Lactobacillus casei were detected and Lactobacillus fermentum was resistant to ceftazidime, tobramycin and amikacin. MIC and MBC of Lactobacillus casei against Shigella flexneri was 62.5 and 62.5. MIC and MBC of Lactobacillus fermentum against Shigella flexneri were 62.5, 15.6 respectively. It shows that Lactobacillus casei and Lactobacillus fermentum can be used as probiotic candidate against Shigella flexneri.
机译:志贺氏菌引起的细菌性痢疾是发达国家和发展中国家以急性腹泻为特征的最重要因素之一。益生菌可降低肠道疾病的强度风险。这项研究评估了干酪乳杆菌和发酵乳杆菌代谢产物对从临床样品中分离的弗氏志贺氏菌的影响。使用基于琼脂的最小抑菌浓度测定法评估了志贺氏杆菌和干酪乳杆菌和发酵乳杆菌的临床样品的抗生素抗性。使用肉汤微量稀释法,最小抑菌浓度(MIC)和最小杀菌浓度(MBC)测定了来自患者的34例弗氏志贺氏菌临床样品的乳酸杆菌代谢产物的抗菌活性。通过浊度测量法绘制标准细菌生长曲线,以比较乳酸杆菌代谢产物对临床样品的抗菌作用。对34个阳性培养的样品进行了抗菌素检测。发现四环素,链霉素和妥布霉素具有抗生素抗性。在这项研究中,检测了干酪乳杆菌中的氯霉素,妥布霉素和阿米卡星的耐药性,发酵乳杆菌对头孢他啶,妥布霉素和阿米卡星具有耐药性。干酪乳杆菌对弗氏志贺氏菌的MIC和MBC分别为62.5和62.5。发酵乳杆菌对弗氏志贺氏菌的MIC和MBC分别为62.5、15.6。它表明干酪乳杆菌和发酵乳杆菌可用作抗弗氏志贺氏菌的益生菌候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号